B

Bioatla Inc
NASDAQ:BCAB

Watchlist Manager
Bioatla Inc
NASDAQ:BCAB
Watchlist
Price: 1.71 USD -14.07% Market Closed
Market Cap: 82.7m USD
Have any thoughts about
Bioatla Inc?
Write Note

Intrinsic Value

BCAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BCAB stock under the Base Case scenario is 1.71 USD. Compared to the current market price of 1.71 USD, Bioatla Inc is Fairly Valued.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCAB Intrinsic Value
1.71 USD
Fairly Valued
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bioatla Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BCAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BCAB?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Bioatla Inc

Provide an overview of the primary business activities
of Bioatla Inc.

What unique competitive advantages
does Bioatla Inc hold over its rivals?

What risks and challenges
does Bioatla Inc face in the near future?

Has there been any significant insider trading activity
in Bioatla Inc recently?

Summarize the latest earnings call
of Bioatla Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bioatla Inc.

Provide P/S
for Bioatla Inc.

Provide P/E
for Bioatla Inc.

Provide P/OCF
for Bioatla Inc.

Provide P/FCFE
for Bioatla Inc.

Provide P/B
for Bioatla Inc.

Provide EV/S
for Bioatla Inc.

Provide EV/GP
for Bioatla Inc.

Provide EV/EBITDA
for Bioatla Inc.

Provide EV/EBIT
for Bioatla Inc.

Provide EV/OCF
for Bioatla Inc.

Provide EV/FCFF
for Bioatla Inc.

Provide EV/IC
for Bioatla Inc.

Show me price targets
for Bioatla Inc made by professional analysts.

What are the Revenue projections
for Bioatla Inc?

How accurate were the past Revenue estimates
for Bioatla Inc?

What are the Net Income projections
for Bioatla Inc?

How accurate were the past Net Income estimates
for Bioatla Inc?

What are the EPS projections
for Bioatla Inc?

How accurate were the past EPS estimates
for Bioatla Inc?

What are the EBIT projections
for Bioatla Inc?

How accurate were the past EBIT estimates
for Bioatla Inc?

Compare the revenue forecasts
for Bioatla Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bioatla Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bioatla Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bioatla Inc compared to its peers.

Compare the P/E ratios
of Bioatla Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Bioatla Inc with its peers.

Analyze the financial leverage
of Bioatla Inc compared to its main competitors.

Show all profitability ratios
for Bioatla Inc.

Provide ROE
for Bioatla Inc.

Provide ROA
for Bioatla Inc.

Provide ROIC
for Bioatla Inc.

Provide ROCE
for Bioatla Inc.

Provide Gross Margin
for Bioatla Inc.

Provide Operating Margin
for Bioatla Inc.

Provide Net Margin
for Bioatla Inc.

Provide FCF Margin
for Bioatla Inc.

Show all solvency ratios
for Bioatla Inc.

Provide D/E Ratio
for Bioatla Inc.

Provide D/A Ratio
for Bioatla Inc.

Provide Interest Coverage Ratio
for Bioatla Inc.

Provide Altman Z-Score Ratio
for Bioatla Inc.

Provide Quick Ratio
for Bioatla Inc.

Provide Current Ratio
for Bioatla Inc.

Provide Cash Ratio
for Bioatla Inc.

What is the historical Revenue growth
over the last 5 years for Bioatla Inc?

What is the historical Net Income growth
over the last 5 years for Bioatla Inc?

What is the current Free Cash Flow
of Bioatla Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bioatla Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bioatla Inc

Current Assets 60.6m
Cash & Short-Term Investments 56.5m
Other Current Assets 4.1m
Non-Current Assets 1.7m
PP&E 1.7m
Current Liabilities 19.5m
Accounts Payable 15.2m
Accrued Liabilities 4.3m
Non-Current Liabilities 19.8m
Other Non-Current Liabilities 19.8m
Efficiency

Earnings Waterfall
Bioatla Inc

Revenue
11m USD
Operating Expenses
-97.2m USD
Operating Income
-86.2m USD
Other Expenses
4.4m USD
Net Income
-81.8m USD

Free Cash Flow Analysis
Bioatla Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BCAB Profitability Score
Profitability Due Diligence

Bioatla Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Years Revenue Growth
Exceptional ROIC
Declining ROE
40/100
Profitability
Score

Bioatla Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

BCAB Solvency Score
Solvency Due Diligence

Bioatla Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Bioatla Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCAB Price Targets Summary
Bioatla Inc

Wall Street analysts forecast BCAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCAB is 9.95 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

Lowest
Price Target
5.05 USD
195% Upside
Average
Price Target
9.95 USD
482% Upside
Highest
Price Target
14.7 USD
760% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BCAB?

Click here to dive deeper.

Dividends

Bioatla Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BCAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BCAB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Bioatla Inc

Country

United States of America

Industry

Biotechnology

Market Cap

82.7m USD

Dividend Yield

0%

Description

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company has initiated a Phase I/II dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.

Contact

CALIFORNIA
San Diego
11085 Torreyana Road
+18585580708.0
www.bioatla.com

IPO

2020-12-16

Employees

56

Officers

Co-Founder, CEO & Chairman
Dr. Jay M. Short Ph.D.
Senior VP & CFO
Mr. Richard A. Waldron
Chief Medical Officer
Dr. Eric L. Sievers M.D.
Chief Accounting Officer, Controller and Corporate Secretary
Mr. Christian J. Vasquez
Senior Vice President of Human Resources
Ms. Susie Melody
Senior Vice President of Research & Development
Dr. Cathy Chang Ph.D.
Show More
Senior Vice President of Technology Development
Dr. Gerhard Frey Ph.D.
Senior Vice President of Intellectual Property & Contracts
Ms. Monica Sullivan
Chief Commercial Officer
Ms. Sheri Lydick
Accounting Manager
Lisa M. Pelton
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCAB stock?

The intrinsic value of one BCAB stock under the Base Case scenario is 1.71 USD.

Is BCAB stock undervalued or overvalued?

Compared to the current market price of 1.71 USD, Bioatla Inc is Fairly Valued.

Back to Top